药物临床试验期间安全性数据快速报告的更新与思考

doi:10.19803/j.1672-8629.20230624

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (1): 98-101.
DOI: 10.19803/j.1672-8629.20230624

药物临床试验期间安全性数据快速报告的更新与思考

刘敏, 陈艳, 刘文东, 王海学^*

国家药品监督管理局药品审评中心, 北京 100076

收稿日期:2023-10-09 出版日期:2024-01-15 发布日期:2024-01-18
通讯作者: ^*王海学,男,博士,主任药师,临床试验管理。
作者简介:刘敏,女,硕士,主管药师,临床试验管理。
基金资助:
国家科技重大专项重大新药创制（2015ZX09501008）

Updates and reflections on expedited reporting of safety information during drug clinical trials

LIU Min, CHEN Yan, LIU Wendong, WANG Haixue^*

Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China

Received:2023-10-09 Online:2024-01-15 Published:2024-01-18

摘要/Abstract

摘要： 目的增强业界对安全性信息快速报告实施要求的进一步理解。方法对《药物临床试验期间安全性数据快速报告常见问答（2.0版）》修订背景信息与变化进行解读分析,包括快速报告范围、时限、方式等。结果与结论 为更好地提升安全性信息报告质量,药品注册申请人作为主体责任人要履行责任,积极与临床试验各参与方沟通交流,尽可能全面收集信息; 药品监管机构应继续提升临床试验期间药物警戒监管能力和水平,完善标准体系建设和操作规范,加强风险评估能力,提高信息化水平,切实保护受试者的安全和权益。

关键词: 临床试验, 药品监管部门, 药品注册, 申请人, 药物警戒, 安全性, 快速报告

Abstract: Objective To advance our understanding of the requirements on implementation of expedited reporting of safety information. Methods The background and changes of FAQ 2.0, including the scope, time limit, and method of expedited reporting, were interpreted and analyzed. Results and Conclusion In order to improve the quality of safety information reports, the applicant, as the main responsible person, should fulfil his responsibility, communicate willingly with all the parties involved in the clinical trial, and collect as much information as possible. The drug regulatory authority should continue to elevate the level of pharmacovigilance during the clinical trial, improve the system of standards and codes for practice, enhance the ability to assess risks, and upgrade informatization so as to protect the safety, rights and interests of the subjects.

Key words: clinical trial, regulatory authorities, drug registration, applicants, pharmacovigilance, safety, expedited reporting

中图分类号:

R951
R994.11

刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.

LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230624

https://www.zgywjj.com/CN/Y2024/V21/I1/98

参考文献

[1] NMPA. The National Medical Products Administration has become a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use[EB/OL].(2017-06-22)[2023-04-24].https://www.nmpa.gov.cn/xxgk/yjshp/yjshpxw/20170622153001224.html.
[2] NMPA. The National Medical Products Administration was elected as a member of the Management Committee of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use[EB/OL].(2018-06-07)[2023-04-24].https://www.nmpa.gov.cn/yaowen/ypjgyw/20180607144001273.html.
[3] NMPA. The National Medical Products Administration held a symposium about China process and prospects of ICH[EB/OL].(2021-04-08)[2023-04-24]. https://www.nmpa.gov.cn/yaowen/ypjgyw/hyxx/20210408145921130.html.
[4] NMPA. Notice on the application of International Conference on Harmonization Tier 2 Guidelines[EB/OL].(2018-01-25)[2023-04-24].https://www.nmpa.gov.cn/yaowen/ypjgyw/hyxx/20210408145921130.html.
[5] ICH Guideline. E2A:Clinical Safety Data Management: Definitions and Standards for Expedited Reporting[EB/OL].(1994-10-27)[2023-05-24].https://database.ich.org/sites/default/files/E2A_Guideline.pdf.
[6] CDE, NMPA. Notice on the release of the FAQ on Expedited Reporting of Safety Data during Drug Clinical Trials.(Version 2.0)[EB/OL].(2023-03-17)[2023-05-24].https://www.cde.org.cn/main/news/viewInfoCommon/ddea289e856a539aa70121ae04ec38ac.
[7] The National People’s Congress of the People’s Republic of China. Drug Administration Law of the People’s Republic of China[EB/OL].(2019-08-26)[2023-04-24].http://www.npc.gov.cn/npc/c30834/201908/26a6b28dd83546d79d17f90c62e59461.shtml.
[8] NMPA. Notice on the Release of the Implementation of Individual Case Safety Reporting E2B(R3) Area Guidelines[EB/OL].(2019-11-22)[2023-06-19].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjzh/20191122091301498.html.
[9] CDE, NMPA.Applicant Window[EB/OL].[2023-06-19].https://tyrz.cde.org.cn/am/UI/Login.
[10] NMPA. Announcement of the State Drug Administration on the Publication of the Code of Practice for the Quality Management of Pharmacovigilance[EB/OL].(2021-05-13)[2023-06-19].https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210513151827179.html.
[11] NMPA. Notice of the National Medical Products Administration on the Issuance of Serious Adverse Event Reporting Management Provisions for Vaccine Clinical Trials(Trial)[EB/OL].(2014-01-17)[2023-05-24].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20140117145701524.html.
[12] EMA. Communication from the commission-detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use(‘CT-3’)[EB/OL].(2011-06-11)[2023-07-06].https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52011XC0611(01).
[13] FDA. Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies.Draft Guidance for Industry[EB/OL].(2021-06)[2023-07-06]. https://www.fda.gov/media/150356/download.
[14] ICH Guideline. E2B(R3): Implementation Guide for Electronic Transmission of Individual Case Safety Reports(ICSRs) E2B(R3) Data Elements and Message Specification[EB/OL].(2016-11-10)[2023-05-24].https://ich.org/page/e2br3-individual-case-safety-report-icsr-specification-and-related-files.
[15] CIOMS Working Group VI on the Management of Safety Information from Clinical Trials, Council for International Organizations of Medical Sciences. Management of Safety Information from Clinical Trials: Report of CIOMS Working Group VI[EB/OL].[2023-05-25].https://cioms.ch/publications/product/management-of-safety-information-from-clinical-trials-report-of-cioms-working-group-vi/.
[16] WANG NP.Pharmacology(药理学)[M]. Shanghai: Shanghai Science and Technology Press, 2006.
[17] State Administration for Market Regulation. Drug Registration Regulation(No.27)[EB/OL].(2020-04-02)[2023-04-24].http://www.ipraction.gov.cn/article/zcfg/bwgz/202004/307960.html.
[18] CDE. Notice on the Release of Standards and Procedures for Expedited Reporting of Safety Data during Drug Clinical Trials[EB/OL].(2018-04-27)[2023-05-26].https://www.cde.org.cn/main/news/viewInfoCommon/f86be6d655db5c711fe660bef22c3bf.
[19] CDE. Notice of application of E2B(R3) Region Implementation Guidelines for individual safety reports during drug clinical trials by the Center of Drug Evaluation[EB/OL].(2022-01-05)[2023-06-20].https://www.cde.org.cn/main/news/viewInfoCommon/42e09b0e50e86c46b38f1f93f983222c.

药物临床试验期间安全性数据快速报告的更新与思考

Updates and reflections on expedited reporting of safety information during drug clinical trials

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	杨波, 王梦娇, 胡丽丽, 王来成, 李倩, 孔飞飞, 吕冬梅, 沈佳妮. 385例PD-1抗肿瘤治疗的安全性研究及风险因素分析[J]. 中国药物警戒, 2024, 21(4): 447-450.
[2]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[3]	顾晓彤, 孙雪林, 郑丽. 治疗念珠菌血症与侵袭性念珠菌感染新药rezafungin药理作用及临床评价研究进展[J]. 中国药物警戒, 2024, 21(4): 469-472.
[4]	刘毅, 覃玲, 郭贤辉, 陈华, 裴宇盛. 热重和差示扫描量热分析技术在药物分析中的应用进展[J]. 中国药物警戒, 2024, 21(3): 283-289.
[5]	张孝明, 吕萍, 胡馨月, 丁晓丽, 李晶, 梁成罡. 酶联免疫法测定甘精胰岛素中单链前体残留研究[J]. 中国药物警戒, 2024, 21(3): 290-294.
[6]	王丹丹, 王莹, 姚令文, 刘芫汐, 金红宇, 马双成. 顶空-气相色谱法测定到手香提取物11种溶剂残留量[J]. 中国药物警戒, 2024, 21(3): 295-299.
[7]	刘琦, 张玉凤, 罗皓, 李歆. 106例安罗替尼临床应用的合理性与安全性分析[J]. 中国药物警戒, 2024, 21(3): 329-334.
[8]	贾茵茵, 张财树, 周颖, 刘丽, 耿颖, 魏宁漪, 钮思静, 陈华, 许卉. 吸入制剂微细粒子空气动力学粒径分布评价方法研究[J]. 中国药物警戒, 2024, 21(2): 141-146.
[9]	柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.
[10]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[11]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	马瑞泽, 陈志海. 抗新型冠状病毒的小分子药物最新研究进展[J]. 中国药物警戒, 2023, 20(9): 961-966.
[14]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[15]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.